Protalix BioTherapeutics Inc. – Filings and Transcripts

NYSE American: PLX
Share price (8/7/26): $2.46
Market cap (8/7/26): $198 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

ended 03/31/25 Q1

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Shelf registration – amended

Shelf registration

Prospectus supplement for primary offering

Registration of securities for employees

Ownership Filter

MAK Capital Fund LP

MAK Capital Fund LP

News Filter

Shareholder Vote Results, Financial Statements or Exhibits

Investor Presentation

Reports First Quarter 2026 Financial and Business Results

Reports Fiscal Year 2025 Financial and Business Results

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio®

Proxies Filter

Definitive proxy

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Scanned paper annual report submission

Notice of effectiveness

Correspondence with the SEC

Scanned paper annual report submission

Letter from the SEC